[类似葡萄糖类-1受体激动剂:精神疾病的新药学治疗选择?]
Hubertus Himmerich1,2,3
1Centre for Research in Eating and Weight Disorders (CREW), Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, SE5 8AB, London, Großbritannien. hubertus.himmerich@kcl.ac.uk.
Der Nervenarzt
|March 5, 2025
概括
葡萄糖类-1 (GLP-1) 受体激活剂和相关药物显示出治疗糖尿病以外的各种疾病的前景,包括神经和精神疾病. 虽然它们通常是安全的,但它们可能会引起胃肠道的副作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
背景情况:
- 类似葡萄糖类-1 (GLP-1) 受体激活剂是一种药物类别,包括阿尔比格卢提德,杜拉格卢提德,埃克萨纳提德,利拉格卢提德,利克西纳提德,或福格利和塞马格卢提德.
- 蒂尔泽帕提德和雷塔图提德是针对GLP-1,GIP和葡萄糖受体的较新的药物,提供更广泛的作用机制.
研究的目的:
- 审查GLP-1受体激动剂超出血糖控制的多方面的作用.
- 探索它们在神经和精神疾病中的潜在治疗应用.
- 要总结与这些药物相关的已知不良影响.
主要方法:
- 对GLP-1受体激动剂和相关化合物研究的文献综述.
- 对作用机制的分析,包括对胰岛素,葡萄糖素,胃排空,食欲和大脑功能的影响.
- 报告的治疗益处和不良反应的汇编.
主要成果:
- GLP-1受体激动剂增强胰岛素分泌,抑制葡萄糖素,减缓胃排空,降低食欲,改善血糖控制.
- 有证据表明大脑中具有神经保护性,抗炎性和抗氧化作用,可能会影响神经发生和多巴胺基通路.
- 初步数据表明,对痴呆症,饮食障碍,抑郁症,焦虑症和物质使用障碍有潜在的益处.
结论:
- GLP-1受体激动剂具有广泛的生理作用,在非代谢条件下具有新兴的治疗潜力.
- 需要进一步的研究,以充分阐明它们的神经生物学机制和在精神和神经疾病中的临床疗效.
- 常见的副作用是胃肠道,但严重的不良事件如胰腺炎和潜在的甲状腺癌风险需要监测.
相关概念视频
01:24Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
01:26Psychosis: Goals of Pharmacotherapy
102
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
102
01:28Psychosis and Antipsychotic Drugs: Overview
170
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
170
01:15Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
01:23Antidepressant Drugs: MAOIs and Other Agents
175
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
175
01:28Drug Therapy
34
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
34